BACKGROUND: Epidemiological and clinical data implicate that in patients with cancer, continued smoking causes progression of cancer growth and resistance to therapy. The carcinogens possess the ability to block apoptosis, an important mechanism in the development of tumors and resistance to chemotherapy. We previously showed that nicotine enhances growth and proliferation in lung cancer. However, the effects of nicotine, a tobacco carcinogen that inhibits apoptosis, have not been studied before in nasal epithelial carcinoma (NC). In this study, we sought to determine the effects of nicotine on chemotherapy-induced apoptosis in human NC. METHODS: Primary human NC cells were grown per protocol, treated with combination chemotherapy, and the apoptosis was assessed by TUNEL (terminal deoxynucleotidyl transferase biotin-dUTP nick end labeling) and DNA fragmentation assays. The regulation of mitogen-activated protein kinase (MAPK) and protein kinase B (AKT) signal transduction pathway was examined by real time quantitative polymerized chain reaction, and immunofluorescent staining assays. RESULTS: Combination chemotherapy with cisplatin (35 microM) plus etoposide (20 microM) caused a significant increase in NC apoptosis compared with single agent alone, and nicotine, in part, inhibited chemotherapy-induced apoptosis in NC. Furthermore, nicotine induced activation of AKT and MAPK pathways, while inhibition of MAPK using U0126 and AKT by phosphatidylinositol 3-kinase inhibitor, LY294002, in part, blocked the antiapoptotic effects of nicotine against cisplatin and etoposide-induced apoptosis in NC. CONCLUSION: Nicotine inhibits chemotherapy-induced apoptosis in NC via the AKT and MAPK-mediated signaling pathways. We speculate that nicotine may play a role in oncogenesis and resistance to cancer therapy in NC.
BACKGROUND: Epidemiological and clinical data implicate that in patients with cancer, continued smoking causes progression of cancer growth and resistance to therapy. The carcinogens possess the ability to block apoptosis, an important mechanism in the development of tumors and resistance to chemotherapy. We previously showed that nicotine enhances growth and proliferation in lung cancer. However, the effects of nicotine, a tobacco carcinogen that inhibits apoptosis, have not been studied before in nasal epithelial carcinoma (NC). In this study, we sought to determine the effects of nicotine on chemotherapy-induced apoptosis in human NC. METHODS: Primary human NC cells were grown per protocol, treated with combination chemotherapy, and the apoptosis was assessed by TUNEL (terminal deoxynucleotidyl transferase biotin-dUTP nick end labeling) and DNA fragmentation assays. The regulation of mitogen-activated protein kinase (MAPK) and protein kinase B (AKT) signal transduction pathway was examined by real time quantitative polymerized chain reaction, and immunofluorescent staining assays. RESULTS: Combination chemotherapy with cisplatin (35 microM) plus etoposide (20 microM) caused a significant increase in NC apoptosis compared with single agent alone, and nicotine, in part, inhibited chemotherapy-induced apoptosis in NC. Furthermore, nicotine induced activation of AKT and MAPK pathways, while inhibition of MAPK using U0126 and AKT by phosphatidylinositol 3-kinase inhibitor, LY294002, in part, blocked the antiapoptotic effects of nicotine against cisplatin and etoposide-induced apoptosis in NC. CONCLUSION:Nicotine inhibits chemotherapy-induced apoptosis in NC via the AKT and MAPK-mediated signaling pathways. We speculate that nicotine may play a role in oncogenesis and resistance to cancer therapy in NC.
Authors: Colleen R Maier; M Christine Hollander; Evthokia A Hobbs; Irem Dogan; R Ilona Linnoila; Phillip A Dennis Journal: Cancer Prev Res (Phila) Date: 2011-10-25
Authors: Jamie S Ostroff; Elyse R Park; Brett M Goshe; Autumn W Rasmussen; Lynne I Wagner; JoRean D Sicks; Ilana F Gareen; Ruth C Carlos; Benjamin A Herman; Angela Wangari Walter; Susan Regan; Douglas E Levy; Irene Mahon; Alona Muzikansky; Jordan M Neil; Michelle Lui; Deepika Dilip; Laura Malloy; Irina Gonzalez; Lucy Finkelstein-Fox; Caitlin McCann; Elissa Perez Journal: BMC Public Health Date: 2022-07-15 Impact factor: 4.135
Authors: Elyse R Park; Jamie S Ostroff; Giselle K Perez; Kelly A Hyland; Nancy A Rigotti; Sarah Borderud; Susan Regan; Alona Muzikansky; Emily R Friedman; Douglas E Levy; Susan Holland; Justin Eusebio; Lisa Peterson; Julia Rabin; Jacob Miller-Sobel; Irina Gonzalez; Laura Malloy; Maureen O'Brien; Suhana de León-Sanchez; C Will Whitlock Journal: Contemp Clin Trials Date: 2016-07-19 Impact factor: 2.226
Authors: Benjamin A Toll; Thomas H Brandon; Ellen R Gritz; Graham W Warren; Roy S Herbst Journal: Clin Cancer Res Date: 2013-04-09 Impact factor: 12.531
Authors: Michael Andrew Yu; Alan Kiang; Jessica Wang-Rodriguez; Elham Rahimy; Martin Haas; Vicky Yu; Lesley G Ellies; Jing Chen; Jian-Bing Fan; Kevin T Brumund; Robert A Weisman; Weg M Ongkeko Journal: PLoS One Date: 2012-12-26 Impact factor: 3.240
Authors: Prasun Guha; Gargi Bandyopadhyaya; Swamy K Polumuri; Saranya Chumsri; Padmaja Gade; Dhananjaya V Kalvakolanu; Hafiz Ahmed Journal: Breast Cancer Res Treat Date: 2014-03-26 Impact factor: 4.624